New combo therapy shows promise in breast cancer biomarker study
NCT ID NCT02999477
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This study tested a combination of chemotherapy (nab-paclitaxel) and immunotherapy (pembrolizumab) in 32 people with hormone receptor-positive breast cancer. The goal was to see how the treatment changed a biomarker called PD-L1 in tumor tissue. Results help researchers understand how the immune system responds to this treatment approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.